You searched for: alogliptínu (Slovakiska - Engelska)

kombinácia alogliptínu s inými antidiabetikami
combination of alogliptin with other anti-diabetic medicinal products

možné účinky alogliptínu na iné lieky
effects of alogliptin on other medicinal products

absolútna biodostupnosť alogliptínu je približne 100 %.
the absolute bioavailability of alogliptin is approximately 100%.

u potkanov sa zaznamenal prestup alogliptínu placentou.
placental transfer of alogliptin occurs in rats.

u potkanov sa zaznamenal prestup alogliptínu cez placentu.
placental transfer of alogliptin occurs in rats.

možnosť odstránenia alogliptínu peritoneálnou dialýzou nie je známa.
it is not known if alogliptin is removed by peritoneal dialysis.

každá tableta obsahuje 25 mg alogliptínu (ako benzoát)
each tablet contains 25 mg alogliptin (as benzoate)

klinické štúdie alogliptínu hlásia nízku incidenciu anafylaktických reakcií.
in clinical studies of alogliptin, anaphylactic reactions were reported with a low incidence.

maximálna odporúčaná denná dávka 25 mg alogliptínu sa nesmie prekročiť.
the maximum recommended daily dose of 25 mg alogliptin should not be exceeded.

každá 25 mg tableta obsahuje alogliptín benzoát zodpovedajúci 25 mg alogliptínu.
each 25 mg tablet contains alogliptin benzoate equivalent to 25 mg alogliptin,

ako preventívne opatrenie je vhodnejšie vyhnúť sa užívaniu alogliptínu počas gravidity.
as a precautionary measure, it is preferable to avoid the use of alogliptin during pregnancy.

najčastejšou nežiaducou reakciou u pacientov liečených 25 mg alogliptínu bola bolesť hlavy.
the most common adverse reaction in patients treated with 25 mg alogliptin was headache.

farmakokinetické vlastnosti alogliptínu u detí a dospievajúcich mladších ako 18 rokov neboli stanovené.
the pharmacokinetics of alogliptin in children and adolescents < 18 years old has not been established.

farmakokinetické vlastnosti alogliptínu u detí a dospievajúcich mladších ako 18 rokov neboli doteraz stanovené.
the pharmacokinetics of alogliptin in children and adolescents < 18 years old has not been established.

každá tableta obsahuje alogliptín benzoát a pioglitazón hydrochlorid zodpovedajúci 25 mg alogliptínu a 30 mg pioglitazónu.
each tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 25 mg alogliptin and 30 mg pioglitazone.

celkovo povedané, odporúčaná denná dávka 25 mg alogliptínu v kombinácii s pioglitazónom zlepšila kontrolu glykémie.
overall, treatment with the recommended daily dose of 25 mg alogliptin in combination with pioglitazone improved glycaemic control.

celkovo povedané, odporúčaná celková denná dávka 25 mg alogliptínu v kombinácii s metformínom zlepšila glykemickú kontrolu.
overall, treatment with the recommended total daily dose of 25 mg alogliptin in combination with metformin improved glycaemic control.

bezpečnosť a účinnosť alogliptínu pri použití v kombinovanej liečbe s tromi liekmi s metformínom a sulfonylureou neboli doteraz úplne stanovené.
the safety and efficacy of alogliptin when used as triple therapy with metformin and a sulphonylurea have not been fully established.

každá tableta obsahuje 25 mg alogliptínu (ako benzoát) a 30 mg pioglitazónu (ako hydrochlorid)
each tablet contains 25 mg alogliptin (as benzoate) and 30 mg pioglitazone (as hydrochloride)

každá filmom obalená tableta 25 mg/30 mg obsahuje alogliptín benzoát a pioglitazón hydrochlorid zodpovedajúci 25 mg alogliptínu a 30 mg pioglitazónu.
each 25 mg/30 mg film-coated tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 25 mg alogliptin and 30 mg pioglitazone.